Cheplapharm patents expiration
1. Valcyte patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6083953 | CHEPLAPHARM | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
Mar, 2015
(9 years ago) | |
|
US6083953 (Pediatric) | CHEPLAPHARM | 2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative |
Sep, 2015
(8 years ago) | |
| US9642911 | CHEPLAPHARM | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(3 years from now) | |
| US8889109 | CHEPLAPHARM | Pharmaceutical dosage forms comprising valganciclovir hydrochloride |
Dec, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Apr 23, 2018 |
| New Dosing Schedule(D-148) | Apr 23, 2018 |
| Pediatric Exclusivity(PED) | Feb 28, 2013 |
| New Dosing Schedule(D-125) | Aug 05, 2013 |
| New Indication(I-604) | Aug 28, 2012 |
Drugs and Companies using VALGANCICLOVIR HYDROCHLORIDE ingredient
Market Authorisation Date: 29 March, 2001
Treatment: Prevention of cmv disease in kidney, heart, and kidney-pancreas transplant patients at high risk (donor cmv seropositive/recipient cmv seronegative)
Dosage: TABLET;ORAL; FOR SOLUTION;ORAL
VALCYTE family patents
2. Xeloda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5472949 | CHEPLAPHARM | N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same |
Dec, 2013
(10 years ago) | |
|
US5472949 (Pediatric) | CHEPLAPHARM | N4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same |
Jun, 2014
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-131) | Dec 10, 2016 |
| Pediatric Exclusivity(PED) | Jun 10, 2017 |
Drugs and Companies using CAPECITABINE ingredient
Market Authorisation Date: 30 April, 1998
Treatment: Method of treating tumors
Dosage: TABLET;ORAL
XELODA family patents
3. Xenical patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6004996 | CHEPLAPHARM | Tetrahydrolipstatin containing compositions |
Jan, 2018
(6 years ago) | |
|
US6004996 (Pediatric) | CHEPLAPHARM | Tetrahydrolipstatin containing compositions |
Jul, 2018
(5 years ago) | |
Drugs and Companies using ORLISTAT ingredient
Market Authorisation Date: 23 April, 1999
Treatment: NA
Dosage: CAPSULE;ORAL
XENICAL family patents
4. Zyprexa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6960577 | CHEPLAPHARM | Combination therapy for treatment of refractory depression |
Nov, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-591) | Mar 19, 2012 |
| New Patient Population(NPP) | Dec 04, 2012 |
| Pediatric Exclusivity(PED) | Jun 04, 2013 |
Drugs and Companies using OLANZAPINE ingredient
Market Authorisation Date: 30 September, 1996
Treatment: Prozac and olanzapine in combination for the acute treatment of treatment resistant depression in adults
Dosage: TABLET;ORAL
ZYPREXA family patents
5. Zyprexa Relprevv patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6169084 | CHEPLAPHARM | 2-methyl-thieno-benzodiazepine formulation |
Sep, 2018
(5 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 11, 2012 |
Drugs and Companies using OLANZAPINE PAMOATE ingredient
Market Authorisation Date: 11 December, 2009
Treatment: A method of treating human suffering from or susceptible to psychosis.
Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
ZYPREXA RELPREVV family patents
6. Zyprexa Zydis patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6960577 | CHEPLAPHARM | Combination therapy for treatment of refractory depression |
Nov, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-591) | Mar 19, 2012 |
| Pediatric Exclusivity(PED) | Jun 04, 2013 |
| New Patient Population(NPP) | Dec 04, 2012 |
Drugs and Companies using OLANZAPINE ingredient
Market Authorisation Date: 06 April, 2000
Treatment: Zyprexa zydis and fluoxetine in combination for the acute treatment of treatment resistant depression in adults
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
ZYPREXA ZYDIS family patents